Author:
van den Brink W.,Belgers M.,Schellekens A. F. A.,van Noorden M. S.,Batalla A.,Luykx J. J.
Reference11 articles.
1. Bay, T., Eghorn, L. F., Klein, A. B., et al. (2014). GHB receptor targets in the CNS: Focus on high-affinity binding sites. Biochemical Pharmacology, 87, 220–228.
2. Bennett, W. R., Wilson, L. G., & Roy-Byrne, P. P. (2007). Gamma-hydroxybutyric acid (GHB) withdrawal: A case report. Journal of Psychoactive Drugs, 39, 293–296.
3. Beurmanjer, H., Luykx, J., De Wilde, B., Van Rompaey, K., Buwalda, V., De Jong, C., Dijkstra, B., & Schellekens, A. (2020). Tapering with pharmaceutical GHB or benzodiazepines for detoxification in GHB-dependent patients: A matched-subject observational study of treatment-as-usual in Belgium and The Netherlands. CNS Drugs, 34(6), 651–659.
4. GHB Monitor via https://nispa.nl/onderzoek/ghb/protocollen.
5. https://www.nrc.nl/nieuws/2016/01/06/ieder-uur-een-buisje-anders-ging-hij-trillen-1574688-2-a791598.